# Intended Use Study of the BD SurePath Plus™ Pap

> **NCT01234480** · — · TERMINATED · sponsor: **Becton, Dickinson and Company** · enrollment: 5859 (actual)

## Conditions studied

- Uterine Cervical Neoplasms
- Uterine Cervical Cancer
- Neoplasms, Squamous Cell
- Neoplasms, Glandular and Epithelial
- Neoplasms by Histologic Type
- Neoplasms
- Papilloma

## Interventions

- **DEVICE:** BD SurePath Plus Pap test
- **DEVICE:** BD SurePath Pap test
- **PROCEDURE:** colposcopy with biopsy/ECC
- **DEVICE:** HPV DNA test

## Key facts

- **NCT ID:** NCT01234480
- **Lead sponsor:** Becton, Dickinson and Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-09
- **Primary completion:** 2012-03
- **Final completion:** 2012-08
- **Target enrollment:** 5859 (ACTUAL)
- **Why stopped:** Decided not to pursue commercialization of the product
- **Last updated:** 2023-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01234480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01234480, "Intended Use Study of the BD SurePath Plus™ Pap". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01234480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*